Using advanced imaging techniques to improve brain cancer diagnosis
Official title: Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI
Run by Centre Paul Strauss · NCT05464992 · Data updated 2026-11-12
This study is testing a new imaging technique to see if adding special scans can help doctors better diagnose brain cancer in patients getting PET/MRI exams.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | Centre Paul Strauss Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | December 28, 2022 |
| Main results expected | December 28, 2036 |
| Study ends | December 28, 2036 |
| Registry record updated | February 2, 2026 |
| Trial ID | NCT05464992 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients scheduled for PET/MRI exams due to glioma or brain metastases.
✕Probably not a fit
Patients with contraindications to MRI or those unable to provide consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the diagnostic capabilities of PET/MRI scans by incorporating Chemical Exchange Saturation Transfer (CEST) imaging. CEST imaging allows for the detection of various metabolites in brain tissues, providing valuable biochemical information that can aid in the evaluation of gliomas and brain metastases. By adding CEST sequences to standard imaging protocols, the study seeks to improve sensitivity and spatial resolution in identifying pathological conditions. Patients undergoing PET/MRI exams for preoperative evaluation or recurrence assessment will be included in this innovative approach.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and better treatment planning for patients with brain tumors.
How similar studies have gone: While CEST imaging is a relatively novel approach, preliminary studies have shown promise in enhancing imaging capabilities for various conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to: * Preoperative evaluation of a cerebral expansion lesion * Evaluation of glioma recurrences * Evaluation of brain metastases * Evaluation of recurrence of metastases Exclusion Criteria: * Contraindication to the realization of an MRI * Minor or patients placed under guardianship or supervision * Patients deprived of liberty * Patients placed under judicial protection * Patients that are not able to express their consent * Pregnant and breastfeeding women
Where it's running
-
France Institut de cancérologie Strasbourg Europe
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Manon VOEGELIN
- Email: promotion-rc@icans.eu
- Phone: (0)368339523
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer
This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.
-
Using MRI to Differentiate Between Brain Tumors and Radiation Effects
This study is testing a new MRI technique to see if it can help tell the difference between brain tumors and radiation damage in people who have had radiation therapy.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.